Cholangitis

The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…

Nearly six months of treatment with the experimental oral candidate linerixibat significantly reduced itch and itch-related sleep problems for adults with primary biliary cholangitis…

The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…

An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…

With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.

Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…

High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…

Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…

Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…

The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…